BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conj…
Biotechnology
US, San Diego [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
BioAtla, Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDBioAtla, Inc. can't present revenue by segment